Provided By Globe Newswire
Last update: Apr 4, 2023
LOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Paris, France, 23-26 April 2023.
Read more at globenewswire.comNASDAQ:IMMX (5/9/2025, 11:19:00 AM)
2.1
-0.04 (-1.87%)
Find more stocks in the Stock Screener